THE EVOLVING ROLE OF SGLT2 INHIBITORS IN MODERN THERAPEUTICS
Keywords:
Empagliflozin, Diabetes mellitus, Heart failure, Chronic Kidney Disease, Metabolic syndrome, Pleiotropic effects, SGLT2 inhibitorsAbstract
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a transformative class of therapeutics, with empagliflozin demonstrating significant clinical benefits beyond glycemic control. This systematic review synthesizes the current evidence on the multifaceted role of empagliflozin, focusing on its applications in diabetes, cardiovascular and heart failure management, renal disease, and other emerging therapeutic areas. We critically evaluate the pharmacological mechanisms, clinical efficacy, and safety profile of empagliflozin, aiming to provide a comprehensive understanding of its position in modern therapeutics. A rigorous methodology was employed to identify and analyze relevant studies, ensuring the inclusion of high-quality evidence while minimizing bias. The findings highlight empagliflozin's robust glycemic efficacy in type 2 diabetes, coupled with its cardioprotective effects, including reduced hospitalization for heart failure and improved cardiovascular outcomes in high-risk patients. Additionally, empagliflozin exhibits renoprotective properties, slowing the progression of chronic kidney disease independent of glycemic control. Emerging evidence suggests potential benefits in metabolic syndrome, non-alcoholic fatty liver disease, and other conditions, though further research is warranted. The review underscores the paradigm shift in therapeutic strategies, where empagliflozin and other SGLT2 inhibitors are increasingly recognized for their pleiotropic effects. Despite its advantages, considerations regarding adverse effects and patient selection remain crucial. This synthesis of evidence positions empagliflozin as a cornerstone in contemporary treatment algorithms, with implications for future research and clinical practice.
Downloads
References
1. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8(8):495-502.
2. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
3. Vallon V. State-of-the-art-review: mechanisms of action of SGLT2 inhibitors and clinical implications. Am J Hypertens. 2024;37(1):1-15.
4. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care. 2016;39(7):1108-1114.
5. Simes BC, MacGregor GG. Sodium-glucose cotransporter-2 (SGLT2) inhibitors: a clinician's guide. Diabetes Metab Syndr Obes. 2019;12:213-225.
6. Packer M, Anker SD, Butler J, Filippatos G, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424.
7. Theofilis P, Sagris M, Oikonomou E, et al. Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes. Diabetes Res Clin Pract. 2022;188:109927.
8. Perrone-Filardi P, Avogaro A, Bonora E, et al. Mechanisms linking empagliflozin to cardiovascular and renal protection. Int J Cardiol. 2017;241:450-456.
9. Perakakis N, Chrysafi P, Feigh M, Veidal SS, et al. Empagliflozin improves metabolic and hepatic outcomes in a non-diabetic obese biopsy-proven mouse model of advanced NASH. Int J Mol Sci. 2021;22(11):6032.
10. Htoo PT, Tesfaye H, Schneeweiss S, et al. Comparative effectiveness of empagliflozin vs liraglutide or sitagliptin in older adults with diverse patient characteristics. JAMA Netw Open. 2022;5(3):e221003.
11. Liakos A, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16(10):984-993.
12. Neumiller JJ. Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context. 2014;3:212262.
13. Levine MJ. Empagliflozin for type 2 diabetes mellitus: an overview of phase 3 clinical trials. Curr Diabetes Rev. 2017;13(4):405-423.
14. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335-1380.
15. Brunton SA. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus. Int J Clin Pract. 2015;69(10):1071-1087.
16. Handelsman Y. Rationale for the early use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes. Adv Ther. 2019;36(10):2567-2586.
17. Laffel LM. Summary of research: efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes. Diabetes Ther. 2024;15(1):123-135.
18. Anderson JE, Wright EE Jr, Shaefer CF Jr. Empagliflozin: role in treatment options for patients with type 2 diabetes mellitus. Diabetes Ther. 2017;8(1):33-56.
19. Voors AA, Angermann CE, Teerlink JR, Collins SP, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568-574.
20. Williams DM, Evans M. Are SGLT-2 inhibitors the future of heart failure treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials. Diabetes Ther. 2020;11(9):1925-1934.
21. Coats AJS, Butler J, Tsutsui H, et al. Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved. J Cachexia Sarcopenia Muscle. 2024;15(1):201-210.
22. Heath R, Johnsen H, Strain WD, Evans M. Emerging horizons in heart failure with preserved ejection fraction: the role of SGLT2 inhibitors. Diabetes Ther. 2022;13(4):643-653.
23. Biegus J, Fudim M, Salah HM, et al. Sodium-glucose cotransporter-2 inhibitors in heart failure: Potential decongestive mechanisms and current clinical studies. Eur J Heart Fail. 2023;25(5):611-622.
24. Thirunavukarasu S, Jex N, Chowdhary A, et al. Empagliflozin treatment is associated with improvements in cardiac energetics and function and reductions in myocardial cellular volume in patients with type 2 diabetes. Circulation. 2021;144(18):1480-1492.
25. Sawicki KT, Ben-Sahra I, et al. SGLT2 inhibition on cardiac mitochondrial function: searching for a sweet spot. J Am Heart Assoc. 2021;10(14):e022131.
26. Hu Z, Ju F, Du L, Abbott GW. Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death. Cardiovasc Diabetol. 2021;20(1):199.
27. Carberry J, Petrie MC, Lee MMY, et al. Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI). Eur J Heart Fail. 2025;27(1):112-120.
28. Yurista SR, Silljé HHW, et al. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail. 2019;21(7):862-873.
29. Philippaert K, Kalyaanamoorthy S, Fatehi M, Long W, et al. Cardiac late sodium channel current is a molecular target for the sodium/glucose cotransporter 2 inhibitor empagliflozin. Circulation. 2021;143(22):2188-2204.
30. Vettor R, Inzucchi SE, Fioretto P. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects. Diabetologia. 2017;60(6):995-1006.
31. Dekkers CCJ, Gansevoort RT, Heerspink HJL. New diabetes therapies and diabetic kidney disease progression: the role of SGLT-2 inhibitors. Curr Diab Rep. 2018;18(5):27.
32. Giorgino F, Vora P, Fenici P, Solini A. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk. Cardiovasc Diabetol. 2020;19(1):143.
33. Akunjee MM, Khosla SG, et al. SGLT2 inhibitors use in kidney disease: what did we learn?. Am J Physiol Endocrinol Metab. 2025;328(2):E112-E125.
34. Gallo LA, Ward MS, Fotheringham AK, Zhuang A, et al. Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Sci Rep. 2016;6:21628.
35. Evans M, Morgan AR, Whyte MB, Hanif W, Bain SC, et al. New therapeutic horizons in chronic kidney disease: the role of SGLT2 inhibitors in clinical practice. Drugs. 2022;82(4):417-432.
36. Balasubramanian P, Wanner C, et al. Empagliflozin and decreased risk of nephrolithiasis: a potential new role for SGLT2 inhibition?. J Clin Endocrinol Metab. 2022;107(11):e4321-e4328.
37. Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79(3):219-230.
38. Shinozaki S, Tahara T, Lefor AK, et al. Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus. J Med Invest. 2020;67(1.2):116-122.
39. Han JH, Oh TJ, Lee G, Maeng HJ, Lee DH, Kim KM, et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE-/- mice fed a western diet. Diabetologia. 2017;60(7):1345-1353.
40. Xu H, Fu J, Tu Q, Shuai Q, Chen Y, Wu F, et al. The SGLT2 inhibitor empagliflozin attenuates atherosclerosis progression by inducing autophagy. J Physiol Biochem. 2024;80(2):315-326.
41. Cheng L, Fu Q, Zhou L, Fan Y, Liu F, Fan Y, Zhang X, et al. Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms. Sci Rep. 2022;12:12453.
42. Bogoviku J, Nguyen TD, Westphal JG, et al. Effects of empagliflozin on uric acid levels during acute heart failure recompensation: A sub-analysis of the EMPAG-HF trial. Eur J Heart Fail. 2025;27(2):294-302.
43. Wu W, Wang Y, Xie J, Fan S. Empagliflozin: a potential anticancer drug. Discover Oncol. 2023;14:87.
44. Bakosh MF, Ghazy RM, Ellakany WI, Kamal A. Empagliflozin as a novel therapy for cirrhotic refractory ascites: A randomized controlled study. Egypt Liver J. 2024;12:34.
45. Daniele AJ, Gregorietti V, Costa D, et al. Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD-PILOT trial. Cardio-Oncology. 2024;10:14.
46. Maiorana A, Tagliaferri F, Dionisi-Vici C. Current understanding on pathogenesis and effective treatment of glycogen storage disease type 1b with empagliflozin: new insights coming from diabetes. Front Endocrinol. 2023;14:1134262.
(CC BY-NC)
. 